3.1 The appraisal committee (section 6) considered evidence submitted by Novartis Pharmaceuticals and a review of this submission by the evidence review group. This appraisal was a Cancer Drugs Fund reconsideration of the NICE technology appraisal guidance on everolimus for the second-line treatment of advanced renal cell carcinoma. The company submission focused on cost-effectiveness analyses using a revised patient access scheme, which provides a simple discount to the list price of everolimus. The level of the discount is commercial in confidence.
3.2 See the committee papers for full details of the Cancer Drugs Fund reconsideration evidence and the history for full details of the evidence used for NICE's original technology appraisal guidance on everolimus for the second-line treatment of advanced renal cell carcinoma.